Leukemia and Lymphoma

The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.

Adolescent, Young Adult Leukemia Survivors Face Higher Long-term Mortality Rates

May 19th 2022, 7:25pm


While 5-year survival in adolescent and young adult leukemia has improved in recent decades, this patient population still faces increased long-term mortality compared with the general public.

Review Highlights Progress and Challenges in Treating HIV/AIDS-Associated Lymphoma

May 16th 2022, 5:20pm


Significant progress has led to improved survival in patients with HIV/AIDS, but lymphoma remains a leading cause of morbidity and mortality in this patient population.

Case Series Suggests Venetoclax Plus Hypomethylating Agent Therapy Tolerable, Effective in Very Elderly AML Patients

May 11th 2022, 3:28pm


Very elderly patients with acute myeloid leukemia have historically been limited to less intensive, less effective treatment regimens. A recent series of cases suggests age alone should not be a limiting factor for effective treatment.

Review Addresses Antifungal Prophylaxis in AML and Provides Guidance for Novel Agents

May 9th 2022, 1:06pm


Patients with acute myeloid leukemia (AML) who have undergone intensive chemotherapy are at a very high risk for invasive fungal disease, and a changing treatment landscape warrants further research on drug-drug interactions and outcomes.

Hypomethylating Agents With Venetoclax Can Be Effective Bridge to Transplant in AML

May 1st 2022, 11:31am


Among a cohort of 88 patients with acute myeloid leukemia who received hypomethylating agents with venetoclax prior to allogeneic hematopoietic cell transplant, 85% had achieved morphologic complete response at 100 days.

Dr Bernice Kwong Explains Dermatological Considerations for Patients With L&L

April 27th 2022, 5:15pm


Bernice Kwong, MD, clinical professor of dermatology, Stanford University, explains what dermatological considerations should be made for patients with leukemia and lymphoma.

Case Study Presents 3 Potential Novel Targets in Acute Myeloid Leukemia

April 27th 2022, 11:47am


Acute myeloid leukemia is a complicated heterogenous hematological cancer with a poor prognosis, but novel targets may lead to improved treatment and outcomes going forward.

AKR1C3 Expression May Hold Potential as a Biomarker, Clinical Target in T-ALL

April 24th 2022, 12:32pm


Aldo-keto reductase 1C3 (AKR1C3) has been identified as a potential biomarker and target in several cancers, and a recent study found it to be a potential biomarker in T acute lymphoblastic leukemia/lymphoma (T-ALL).

Neurocognitive Changes After CAR T-Cell Therapy for NHL Similar to Other Cancers

April 20th 2022, 10:49am


With an increasing number of longer-term survivors treated with chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma (NHL), more research is needed to confirm its effects on neurocognitive performance.

City of Hope’s Alvarnas: Payers Must Recognize Cancer Care Is Different

April 17th 2022, 12:00pm


Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope in Duarte, California, spoke March 4 at the closing session of the Association for Community Cancer Centers (ACCC) Annual Meeting & Cancer Business Summit in Washington, DC.